Jonathan Huff

I don't generally deal in absolutes. Kubernetes Devops

[Jonathan Huff @JonKHuff]

You can buy each piece of the SIP mask valve separately and in bulk, and save a fair bit. Especially important if you use your SIP a lot or need to supply a covid safer event. More links in the 🧵

[Dr. Sean Mullen @drseanmullen]

Hey Airborne Aware, Covid Competent, Precautionary Principle Enthusiasts…

I need your help. I’m developing a Human Identity Ontology of sorts… for things like Physical Activity Identity, Pro-Environmental Identity, Playful Identity, Creative and Performing Arts Identity, etc.

I need all the self-definitions or labels you use to describe yourselves regarding being CC, competent, knowledgeable, aware, … If you catch my drift, can you comment on how you identify yourself in this respect?

Only do this if it’s really important to how you see yourself and if it’s unique and different from what I’ve already listed. I’m trying to capture the full breadth of the construct and the essence of being woke to clean air, masking, airborne transmission and precautions.

[Jim the hermit @SleepyJim0]

Doctor: you’re not capable of working
Politicians: yes you are

Virologist: you really don’t want to be infected with SARS2 repeatedly
Politicians: it’s fine don’t concern yourself

Climatologists: we need to stop burning fossil fuels or billions will die
Politicians: drill away

[Jonathan Huff @JonKHuff]

@antiviral_mktng I saw that too and was like "they're considering evidence again? When did that happen?"

[Al Haddrell @ukhadds]

I’m proud to have our latest research published on how long #SARSCoV2 remains infectious while airborne! We studied the fundamental processes that drive the loss of viral infectivity in the aerosol phase. #COVIDisAirborne

Here’s a thread going over some of the findings.

[Nukit @NukitToBeSure]

Can now make 1-, 2-, and 4-filter versions. Easy filter changes, no tape or disassembly. Just slide the filter in the slot.

Automatic alignment holes for gluing work with pins made from cut lengths of 3D printer filament.

Can locate the power cable pass-through wherever you like🤓

[Dr. bird 🌻 | Inspiring Change @bbirdbPhD]

Did you know that I’m a newly car homeless person because I was fired for telling the truth about Charlie Kirk last year after living entirely alone for 6 years in an apartment and I’m about to travel across the country to live with my cousin (who’s wanted me to move in with…

[Jonathan Huff @JonKHuff]

@DonEford Yeah, measured does not mean its the widespread response. The *outlier* is at 50% right near the vaccination. And falling rapidly after that. 🫠

[Don Ford - The People's Strategist - @DonEford]

It's a little smashed with data...

The point is that while many people say that all COVID vaccines wane in the same way, this is a fundamentally false statement.

mRNA does not create Long-Lived Plasma Cells (LLPCs).

The adjuvant in Nuvavaxovid, Matrix-M, does.

So, no, they do not wane the same.

[holocene @holo_cene]

only 2 people bought online tickets since this post 😭 i still need 120 online or IRL so i don’t lose money 😣 please share to your Parisian or alternative music lovers friends!!

[Don Ford - The People's Strategist - @DonEford]

There are probably still a few typos...

I have 2.5 hours to catch them and turn this in.

Not bad for four hours.

The extra link has been removed because the project isn't finished, but it should be done by the time I present this.

https://t.co/cBvnreMAEx

[Jonathan Huff @JonKHuff]

@DonEford Excellent points and I love saying directly that their influence should be disregarded since they left and never had the qualities necessary for their jobs let alone for their harmful recommendations regarding vaccine policy

[Don Ford - The People's Strategist - @DonEford]

I'm still trying to raise money, and I've already raised $200 of this week's goal.

https://t.co/9DWoxZiUfn

[Jonathan Huff @JonKHuff]

@ghhughes @LazarusLong13 Oh no! One of the most important and innovative masks... does that mean Redimask is no more?

[Fusion Prog Guy @ fusionprogguy.bsky.social @FusionProgGuy]

This is how I add two exhalation valves to my KN95 ZimiAir respirators. ZimiAir sells a tool for cutting 28mm holes and you can reuse the valves from masks sold with single valves like the ZM8210F.
https://t.co/3AzCo3YTiD

[Jonathan Huff @JonKHuff]

@oldfshndanne @ghhughes @LazarusLong13 @michael_hoerger The moldex Airwave M4620 is designed to be reused several times, but is a disposable respirator. The build and the filter performance definitely inspire confidence. So it just has to do with whether it fits you. Probably it does!

[Biff #SARSisAirborne 🍉 @Biff234523]

💊🧵 Thoughts on Xocova/Ensitrelvir, the drug that everyone is talking about today after Nature recently described it as “a pill that can prevent COVID after exposure to infected people.”

For starters, none of this data is new. @ShionogiUS published topline data for SCORPIO-PEP, the trial showing that Xocova is beneficial in post-exposure prophylaxis, in March of 2025: https://t.co/CLYcAU5UwX

Yesterday, the full peer-reviewed results from the SCORPIO-PEP trial were published in the New England Journal of Medicine, which is why everyone is suddenly talking about them: https://t.co/Dxv0lhS2CM

After that data was released in March 2025, Shionogi then submitted applications with the Japanese government and with the US FDA for the indication of post-exposure prophylaxis: https://t.co/MhB5ThrjO9

In Japan, this drug is not new at all. It has been approved for the treatment of COVID-19 since 2022. And, 2 months ago in March 2026, Japan did indeed issue approval for that indication of post-exposure prophylaxis: https://t.co/suCGo4LGCW

For @US_FDA , the decision date that they have set is coming up next month, on June 16th.

In my view, we’re going to need all the help that we can get to push this approval through, because the FDA offices that will need to issue an approval are currently in complete turmoil:

• Earlier this week, Politico announced that FDA commissioner Makary is resigning, and will be replaced by acting commissioner Kyle Diamantas: https://t.co/pQ06YqbbOb

• The FDA’s Center for Drug Evaluation and Research (CDER) is now led by Tracy Beth Høeg, one of the worst anti-science hacks that this administration has to offer. Just last week, it was widely reported that she personally got involved against Sanofi’s type 1 diabetes drug in a disagreement with staff: https://t.co/CLfbj8OKSF

• Within CDER, the Office of Infectious Diseases (which Xocova approval goes through) currently has no director - Adam Sherwat left the FDA last month: https://t.co/AyHXTn15SI

If you would like to help urge the FDA to approve Xocova, there is an active petition you can sign here: https://t.co/mWDGPiR2wp

Now, what exactly is Xocova, and what is it capable of?

When you strip away the flashy headline from Nature, Xocova is the same class of drug as Paxlovid - a 3CL protease inhibitor. It’s just essentially a “2nd generation” version.

It’s a very encouraging step up from Paxlovid, because it’s very obviously a bit more potent, it comes with slightly less side effects, and it also has less drug interactions. That’s all great, and those advantages highlight why it’s important to get this on the market.

It’s going to be good for lowering viral load during an acute infection, if taken within the first couple days of symptoms, but probably still not very helpful at preventing long-term damage or Long COVID.

Just like Paxlovid, it’s going to be an important part of polytherapy for Long COVID driven by viral persistence. The issue there is that you need a longer course of these antivirals than most physicians are willing to prescribe, and most insurance companies are willing to cover. And it’s not effective as a monotherapy, you need to pair these oral antivirals with other therapies for better coverage (eg. monoclonal antibodies and Novavax, and potentially even a 2nd antiviral like Remdesivir)

And, indeed, as Nature points out, it does appear to be somewhat beneficial for post-exposure prophylaxis, reducing COVID incidence from 9% to 2.9%. This initial data is encouraging that Xocova could potentially be another Swiss cheese layer / tool in our toolbox, but not a game-changing silver bullet. Notably, nobody should really be expecting to use or rely on Xocova in a way that they wouldn’t be open to using or relying on Paxlovid in the present.